When analyzing neuroimaging for atrophy in patients experiencing memory decline, ventricular atrophy seems to provide a more reliable indication than sulcal atrophy. In our clinical practice, we trust the total score from the scale to be a valuable asset.
.

While transplant-related deaths have decreased, patients undergoing hematopoietic stem cell transplants frequently face concurrent short-term and long-term morbidities, diminished quality of life, and deficiencies in psychosocial well-being. Numerous studies have delved into the variations in post-transplant quality of life and emotional profiles among patients who have undergone autologous and allogeneic hematopoietic stem cell transplants. Reported findings on quality of life in patients receiving allogeneic hematopoietic stem-cell transplants have shown a pattern of similar or worse outcomes, but the results across different studies are inconsistent. Our research aimed to assess the influence of the type of hematopoietic stem cell transplantation on the patient experience, encompassing their well-being and emotional responses.
At St. István and St. László Hospitals in Budapest, 121 patients with a variety of hematological diseases underwent hematopoietic stem-cell transplantation. Medial meniscus A cross-sectional design characterized the study. Employing the Hungarian rendition of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale, the quality of life was evaluated. Assessments of anxiety and depressive symptoms involved the application of the Spielberger State-Trait Anxiety Inventory (STAI) and the Beck Depression Inventory (BDI), respectively. Basic sociodemographic and clinical variables were similarly logged. To analyze comparisons between autologous and allogeneic recipients, a t-test was utilized in cases of normally distributed variables, whereas a Mann-Whitney U test was employed otherwise. A stepwise multiple linear regression analysis was undertaken to ascertain the risk factors which correlate to quality of life and affective symptoms across each defined group.
The autologous and allogeneic transplant groups displayed similar outcomes in terms of quality of life (p=0.83) and affective symptoms (pBDI=0.24; pSSTAI=0.63). Allogeneic transplant patients' BDI scores revealed mild depressive symptoms; however, their STAI scores mirrored the general population's results. Among allogeneic transplant patients, those with graft-versus-host disease (GVHD) displayed more pronounced clinical severity (p=0.001), compromised functional status (p<0.001), and a greater reliance on immunosuppressive therapy (p<0.001) relative to those without GVHD. Patients with graft-versus-host disease displayed a higher incidence of severe depression (p=0.001) and constant anxiety (p=0.003), in contrast to those without the condition. The quality of life of both the allo- and autologous groups was inversely correlated with the presence of depressive symptoms, anxiety, and co-occurring psychiatric conditions.
Allogeneic transplant patients experienced a decline in quality of life due to the severe somatic symptoms associated with graft-versus-host disease, often presenting as depressive and anxious states.
.

Cervical dystonia (CD), the most prevalent form of focal dystonia, typically involves challenges in precisely pinpointing the affected muscles, calculating the ideal botulinum neurotoxin type A (BoNT-A) dose, and achieving accurate injection targeting. Biomimetic water-in-oil water By comparing local and international center data, the present study aims to identify population and methodological disparities, ultimately improving the standard of care for Hungarian CD patients.
A cross-sectional analysis was conducted on the data collected retrospectively from all consecutive CD patients who received BoNT-A injections at the botulinum neurotoxin outpatient clinic of the University of Szeged's Department of Neurology between August 11th and September 21st, 2021. Calculations of the frequency of involved muscles, as dictated by the collum-caput (COL-CAP) concept, and the parameters for BoNT-A formulations, delivered via ultrasound (US) guidance, were compared against current international data.
The current study involved a group of 58 patients (19 male and 39 female), whose average age was 584 years (with a standard deviation of ± 136, and an age range from 24 to 81 years). The most frequent subtype was torticaput, representing 293%. A significant portion of patients, 241 percent, displayed tremor symptoms. A significant proportion of injected muscles involved trapezius, specifically 569% of all cases, while levator scapulae injections amounted to 517%, followed by splenius capitis (483%), sternocleidomastoid (328%), and semispinalis capitis (224%). The mean injected dose for onaBoNT-A, incoBoNT-A, and aboBoNT-A was calculated and presented below. onaBoNT-A's mean dose was 117 units, with a standard deviation of 385 units and a range of 50 to 180 units. IncoBoNT-A's mean dose was 118 units, with a standard deviation of 298 units and a range of 80 to 180 units. Finally, aboBoNT-A exhibited a mean dose of 405 units, with a standard deviation of 162 units and a range of 100 to 750 units.
Although both the current and multicentre studies utilized the COL-CAP approach and US-guided BoNT-A injections, they showed comparable results; yet, enhanced differentiation of torticollis subtypes and increased injections of the obliquus capitis inferior, particularly in cases of no-no tremor, are crucial considerations.
.

The use of hematopoietic stem cell transplantation (HSCT) proves to be one of the most efficacious treatment modalities for a wide spectrum of malignant and non-malignant diseases. Our study's objective was to uncover early EEG irregularities in patients undergoing allogeneic and autologous HSCT, who were also undergoing treatment for potentially life-threatening non-convulsive seizures.
Fifty-three patients were the subjects of the study's analysis. Recorded information included patient's age, gender, the HSCT type (allogeneic or autologous), and the treatment strategies implemented before and after the procedure of hematopoietic stem cell transplantation. EEG monitoring was performed on all patients twice—first on the first day of hospitalization and again a week after the beginning of conditioning regimens and HSCT.
The pre-transplant EEG findings, upon scrutiny, indicated normal EEGs in 34 patients (64.2%), contrasting with 19 patients (35.8%) who presented with abnormal EEGs. Upon transplantation, EEG evaluation indicated normal patterns in 27 (509%) patients, 16 (302%) patients had a basic activity disorder, 6 (113%) patients showed focal anomalies, and 4 (75%) had generalized anomalies. Post-transplant EEG analysis revealed a significantly higher rate of anomalies in the allogeneic group compared to the autologous group (p<0.05).
The risk assessment for epileptic seizures should be an integral part of the post-transplant care for HSCT patients. Non-convulsive clinical manifestations require timely diagnosis and treatment, making EEG monitoring essential.
.

IgG4-related (IgG4-RD) disease, a relatively recently discovered chronic autoimmune condition, has the potential to impact any organ system. This medical condition is not common. While primarily manifesting systemically, it can nonetheless present in an isolated fashion within a single organ. Our report features an elderly male patient's case study affected by IgG4-related disease (IgG4-RD), where diffuse meningeal inflammation and hypertrophic pachymeningitis were observed, along with one-sided cranial nerve and intraventricular space involvement.

Autosomal dominant cerebellar ataxias (ADCA), a term often used synonymously with spinocerebellar ataxias (SCA), are a group of progressive neurodegenerative diseases that demonstrate a remarkable degree of variability in both their clinical presentations and genetic underpinnings. In the span of the last ten years, twenty genes pertinent to SCAs were found. Chromosome 16p13 houses the STUB1 gene (STIP1 homology and U-box containing protein 1, NM 0058614), which encodes a multifunctional E3 ubiquitine ligase, specifically CHIP1. In 2013, the genetic link between STUB1 and autosomal recessive spinocerebellar ataxia 16 (SCAR16) was established. This was followed by the 2018 publication by Genis et al., which demonstrated a further connection between heterozygous STUB1 mutations and the autosomal dominant spinocerebellar ataxia 48 (SCA48), in accordance with reference 12. A preliminary analysis of studies 2-9 demonstrates the identification of 28 French, 12 Italian, 3 Belgian, 2 North American, 1 Spanish, 1 Turkish, 1 Dutch, 1 German, and 1 British SCA48 families. Research in these publications highlights SCA48 as a progressive neurological disorder appearing later in life, characterized by cerebellar dysfunction, cognitive decline, psychiatric symptoms, dysphagia, hyperreflexia, urinary complications, and movement disorders like parkinsonism, chorea, dystonia, and, on rare occasions, tremor. Cerebellar atrophy, impacting both the vermis and the hemispheres, was a consistent finding in the brain MRIs of all SCA48 patients. This atrophy was most severe in the posterior regions, specifically lobules VI and VII, in the majority of cases studied. 2-9 T2-weighted imaging (T2WI) hyperintensity was identified in the dentate nuclei (DN) of a number of Italian patients. Additionally, the most recent publication highlighted modifications to DAT-scan imaging in certain French families. Central and peripheral nervous system evaluations, conducted via neurophysiological examinations, yielded no abnormalities, consistent with findings from references 23 and 5. TAK-981 cell line The findings of the neuropathological examination underscored definite cerebellar atrophy and cortical shrinkage, with the severity demonstrating a spectrum. Purkinje cell loss, p62-positive neuronal intranuclear inclusions observed in a portion of cases, and tau pathology identified in one patient, are features identified during the histopathological assessment. This paper focuses on the clinical and genetic presentation of the first Hungarian SCA48 patient, highlighted by a novel heterozygous missense mutation in the STUB1 gene.